Skip to main content

Advertisement

SpringerLink
Log in

Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

The MAGIC trial has shown perioperative chemotherapy does significantly improve overall survival of patients with gastric and esophagogastric junction carcinoma. The approach to evaluate the effectiveness of adjuvant chemotherapy is urgent in clinical practice.

Methods

Totally, 264 patients with locally advanced gastric carcinoma (including esophagogastric junction carcinoma) treaded by perioperiate chemotherapy (SOX or XELOX) from May 2012 to December 2017 in our cancer center were included. Tumor response was evaluated by tumor regression grade (TRG, Mandard system) and Response Evaluation Criteria in Solid Tumor (RECIST v1.1). The clinical characteristics and the effect on survival were analyzed.

Result

Univariate analysis showed TRG was correlated to tumor size, Lauren classification, grade of differentiation, histological type, postsurgical T category (ypT), postsurgical N category (ypN), vascular invasion or lymphatic invasion and so on. However, only Lauren classification and ypT were independent factors for TRG. On contrary to RECIST, TRG was founded to be a prognostic factor for DFS and OS on univariate analysis. Cox proportional hazards were established to evaluate the relationship among TRG, clinical-pathological factors and survival. On multivariate analysis, the chemotherapy cycle, Lauren classification, vascular invasion or lymphatic invasion, ypN and postsurgical pathologic stage were independent factors for OS and DFS, while TRG were negatively correlated to survival.

Conclusion

TRG seems to be a promising prognostic indicator and it predicts the prognosis of patients with locally advanced gastric cancer after adjuvant chemotherapy more reasonably in comparisons to RECIST v1.1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300. https://doi.org/10.3322/caac.20073

    Article  PubMed  Google Scholar 

  2. Liu YY, Fang WL, Wang F et al (2017) Does a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer?-Time to embrace a new digit. Oncologist 22:97–106. https://doi.org/10.1634/theoncologist.2016-0239

    Article  PubMed  Google Scholar 

  3. Smyth EC, Fassan M, Cunningham D et al (2016) Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol 34:2721–2727. https://doi.org/10.1200/JCO.2015.65.7692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Giampieri R, Del PM, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R (2018) Optimal management of resected gastric cancer. Cancer Manag Res 10:1605–1618. https://doi.org/10.2147/CMAR.S151552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20. https://doi.org/10.1056/NEJMoa055531

    Article  CAS  PubMed  Google Scholar 

  6. van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084. https://doi.org/10.1056/NEJMoa1112088

    Article  PubMed  Google Scholar 

  7. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma Clinicopathol correlations. Cancer 73:2680–2686

    Article  CAS  PubMed  Google Scholar 

  8. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112. https://doi.org/10.1007/s10120-011-0041-5

    Article  Google Scholar 

  9. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530. https://doi.org/10.1002/cncr.11660

    Article  PubMed  Google Scholar 

  10. Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696. https://doi.org/10.1200/JCO.2005.02.1329

    Article  PubMed  Google Scholar 

  11. Wang FH, Shen L, Li J et al (2019) The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond) 39:10. https://doi.org/10.1186/s40880-019-0349-9

    Article  Google Scholar 

  12. Li T, Chen L (2011) Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 14:104–106

    PubMed  Google Scholar 

  13. Cunningham D, Okines AF, Ashley S (2010) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362:858–859. https://doi.org/10.1056/NEJMc0911925

    Article  CAS  PubMed  Google Scholar 

  14. Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721. https://doi.org/10.1200/JCO.2010.33.0597

    Article  CAS  PubMed  Google Scholar 

  15. Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321. https://doi.org/10.1016/S0140-6736(11)61873-4

    Article  CAS  PubMed  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  17. Nakata B, Chung KH, Muguruma K, Yamashita Y, Inoue T, Matsuoka T, Onoda N, Kato Y, Sakurai M, Sowa M (1998) Changes in tumor marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma. Cancer 83:19–24

    Article  CAS  PubMed  Google Scholar 

  18. Robb WB, Mariette C (2012) Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy. Recent Results Cancer Res 196:241–268. https://doi.org/10.1007/978-3-642-31629-6_17

    Article  PubMed  Google Scholar 

  19. Bain GH, Collie-Duguid E, Murray GI et al (2014) Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br J Cancer 110:1525–1534. https://doi.org/10.1038/bjc.2014.45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhu Y, Sun Y, Hu S, Jiang Y, Yue J, Xue X, Yang L, Xue L (2017) Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol 17:41. https://doi.org/10.1186/s12876-017-0598-5

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G, Barni S (2017) Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies. Eur J Surg Oncol 43:1607–1616. https://doi.org/10.1016/j.ejso.2017.03.001

    Article  CAS  PubMed  Google Scholar 

  22. Schmidt T, Sicic L, Blank S et al (2014) Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 110:1712–1720. https://doi.org/10.1038/bjc.2014.94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, Pugliese R, Ferrari G (2017) Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol 8:1018–1025. https://doi.org/10.21037/jgo.2017.08.13

    Article  PubMed  PubMed Central  Google Scholar 

  24. Park SR, Lee JS, Kim CG, Kim HK, Kook MC, Kim YW, Ryu KW, Lee JH, Bae JM, Choi IJ (2008) Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 112:2368–2376. https://doi.org/10.1002/cncr.23483

    Article  PubMed  Google Scholar 

  25. Neves FEH, de Sant’Ana RO, Nunes LV, Pires AP, da Cunha MD (2017) Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS 125:79–84. https://doi.org/10.1111/apm.12642

    Article  Google Scholar 

  26. Yoshikawa T, Tanabe K, Nishikawa K et al (2014) Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. Ann Surg Oncol 21(Suppl 3):S385–S389. https://doi.org/10.1245/s10434-014-3615-8

    Article  PubMed  Google Scholar 

  27. Kurokawa Y, Shibata T, Sasako M, Sano T, Tsuburaya A, Iwasaki Y, Fukuda H (2014) Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer 17:514–521. https://doi.org/10.1007/s10120-013-0294-2

    Article  CAS  PubMed  Google Scholar 

  28. Zu H, Wang H, Li C, Xue Y (2014) Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol 7:5692–5700

    PubMed  PubMed Central  Google Scholar 

  29. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR (2006) Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243:74–81

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ikoma Naruhiko, Hofstetter Wayne L, Estrella Jeannelyn S, Das Prajnan, Minsky Bruce D, Fournier Keith F, Mansfield Paul F, Ajani Jaffer A, Badgwell Brian D (2018) The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol 117(8):1721–1728. https://doi.org/10.1002/jso.25081

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Xing Xu and Guoliang Zheng contributed equally to this work.

Authors and Affiliations

  1. Department of Gastric Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning, People’s Republic of China

    Xing Xu, Guoliang Zheng, Tao Zhang, Yan Zhao & Zhichao Zheng

  2. China Medical University, No.77 Puhe Road, Shenbei New District, Shenyang, Liaoning, People’s Republic of China

    Xing Xu

Authors
  1. Xing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guoliang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhichao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Xing Xu searched and reviewed the literature, designed the research and wrote the paper. Guoliang Zheng designed the research and provided the clinical data. Yan Zhao performed statistical analysis. Tao Zhang reviewed the literature and interpreted the paper. Zhichao Zheng participated in reviewing the literature, designing the research, revising and writing the paper.

Corresponding author

Correspondence to Zhichao Zheng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest

Ethical approval

This study was approved by the Ethics Committee of Liao Ning Cancer Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, X., Zheng, G., Zhang, T. et al. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Cancer Chemother Pharmacol 84, 635–646 (2019). https://doi.org/10.1007/s00280-019-03893-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03893-4

Keywords

Search

Navigation